Immune Design is a clinical stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design’s clinical programs are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM.
Oct 4, 2016
Immune Design Appoints Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer
Sep 28, 2016
Aug 9, 2016 at 1:30 PM PT
Jun 8, 2016 at 5:00 PM ET
(Please note: Webcast will begin at 5:30 p.m. ET)